COPI Is Required for Enterovirus 71 Replication by Wang, Jianmin et al.
COPI Is Required for Enterovirus 71 Replication
Jianmin Wang, Zhiqiang Wu, Qi Jin*
State Key Laboratory for Molecular Virology and Genetic Engineering, Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical
College, Beijing, People’s Republic of China
Abstract
Enterovirus 71 (EV71), a member of the Picornaviridae family, is found in Asian countries where it causes a wide range of
human diseases. No effective therapy is available for the treatment of these infections. Picornaviruses undergo RNA
replication in association with membranes of infected cells. COPI and COPII have been shown to be involved in the
formation of picornavirus-induced vesicles. Replication of several picornaviruses, including poliovirus and Echovirus 11
(EV11), is dependent on COPI or COPII. Here, we report that COPI, but not COPII, is required for EV71 replication. Replication
of EV71 was inhibited by brefeldin A and golgicide A, inhibitors of COPI activity. Furthermore, we found EV71 2C protein
interacted with COPI subunits by co-immunoprecipitation and GST pull-down assay, indicating that COPI coatomer might
be directed to the viral replication complex through viral 2C protein. Additionally, because the pathway is conserved among
different species of enteroviruses, it may represent a novel target for antiviral therapies.
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Introduction
The enteroviruses belong to the family of Picornaviridae. Many
enteroviruses cause disease in humans, but the infections are
generally mild or asymptomatic. However, enteroviruses may also
result in serious or even fatal disease. EV71 can lead to serious
neurological diseases in infants and children, such as aseptic
meningitis, encephalitis, and acute flaccid paralysis and even death
[1,2]. EV71 has a ,7.4 kb positive-sense, single-stranded RNA
genome, which has a single open reading frame encoding
a polyprotein flanked by 59- and 39-untranslated regions (UTRs).
It has a small, viral protein, VPg, linked to the 59 end of the
genomic RNA, which is involved in the initiation of viral RNA
genome replication. During infection, Scavenger receptor B2
(SCARB2) and P-selectin glycoprotein ligand-1 (PSGL-1) work as
cellular receptors and mediate the attachment of EV71 to cells
[3,4]. After invading into cells, EV71 uses a mechanism of
translation initiation that starts with direct binding of the ribosome
to internal ribosome entry site (IRES), which lies in the 59UTR,
allowing viral gene expression to occur in a cap-independent
manner while host cell translation is shut down [5]. Since an
outbreak in Malaysia in 1997 [6], EV71 outbreaks have been
frequently observed in Western Pacific Region countries, including
in Australia in 1999 [7,8], Singapore in 2000 [9], Japan in 1997
and 2000 [10,11], and Taiwan in 1998 [12]. Sporadic epidemic or
outbreaks of EV71 infection were also reported after 2000
[13,14,15,16].
Picornaviruses are non-enveloped, positive-strand RNA viruses.
All positive-strand RNA viruses undergo RNA replication in
association with membranes of infected cells [17]. However,
Picornaviruses generally do not use native organelle membranes
for replication but induce the formation of novel cytoplasmic
vesicular compartments in infected cells [18,19]. These mem-
branes can be derived from a variety of sources within the host
cell, including the endoplasmic reticulum (ER), Golgi apparatus,
mitochondria, or from the endolysosomal compartment [20].
These vesicles are the sites of viral RNA replication and are
essential for replication. However, the mechanism by which
piconaviruses induce this vesicular compartment and direct their
RNA replication complex to these specific intracellular mem-
branes, and the cellular components involved in this process, are
not well established. The identification of host proteins and
pathways used by viruses to complete their life cycles has given us
insights into both host-pathogen interactions and provide potential
as novel antiviral targets. Coat protein complex I (COPI) and
COPII vesicles are essential components of the trafficking
machinery cycling between the ER and Golgi [21]. Each complex
is a multisubunit complex. COPI is composed of the seven
coatomer subunits and the ADP ribosylation factor (ARF)
dependent GTPase. The subunits include aCOP, bCOP,
b9COP, cCOP, dCOP, eCOP and fCOP. Two protein hetero-
dimers form the COPII complex, the Sec23p/Sec24p heterodimer
and the Sec13p/Sec31p heterotetramer. COPI vesicles mediate
cargo transport from the Golgi back to the ER, including escaped
ER-resident proteins, while COPII mediates transport of proteins
and lipids from the ER to the Golgi [21]. COPI is also required for
limiting lipid storage and lipid homeostasis [22]. Immunoisolation
and immunoelectron microscopy revealed that COPII were
associated with poliovirus-induced cytoplasmic vesicles
[23,24,25]. COPI activity is also required for poliovirus, EV11
and hepatitis C virus (HCV) [26,27]. Brefeldin A (BFA), an
inhibitor of COPI activity, has been shown to strongly inhibit viral
RNA replication of poliovirus and EV11 [27,28,29]. Replication
of coxsackievirus A21 (CVA21) and coxsackievirus B3 (CVB3) is
also inhibited by BFA [30]. But BFA has little effect on foot-and-
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(EMCV) infection and only partially repressive to Parechovirus 1
[27,31]. Genome-wide RNA interference screening revealed that
picorna-like virus, Drosophila C virus (DCV), also recruited COPI
proteins to achieve viral replication [32].
In this study, using a loss of function assay based on small
interfering RNA (siRNA), we were able to identify that COPI but
not COPII was required for efficient EV71 replication. Loss of
COPI activity protected cells from EV71 infection. Replication of
EV71 was also strongly inhibited by BFA and GCA. Furthermore,
we demonstrated that subunits of COPI interacted with viral
protein 2C. This result suggested that COPI might be recruited to
the viral replication complex through 2C, also COPI might be
coupled with protein 2C to fulfill its function in virus life cycle.
Results
COPI but not COPII is required for EV71 replication
We used siRNA against aCOP, f1COP, Sec23p, and Sec13p to
block the activity of each complex. siRNA was introduced into RD
cells by oligofectamine according to the manufacturer’s instruc-
tions. siRNA targeting EV71 VP2 was synthesized according to
the stealth-990 sequence and transfected as positive control [33].
Nontargeting siRNA was used as negative control. After 72 hours,
RD cells were infected with EV71 at 0.1 multiplicity of infection
(MOI). Cells were harvested and total cellular RNA was extracted
at 24 hours post infection (hpi). Viral genome copies in cultured
cells were determined for each group by quantitative real-time
PCR. The copy number of GAPDH was used as an internal
control. The copy numbers of the corresponding COPI/COPII
subunits were also determined to monitor the efficacy of each
siRNA. As shown in Figure 1A, compared with mock-transfected
control, siRNA targeting EV71 VP2 strongly inhibited EV71
replication to around 20%, while in negative control group
replication for EV71 remained unchanged. Furthermore, in
contrast with mock-transfected control and negative control, both
siRNA duplexes depleted aCOP mRNA transcript levels to
around one third (Figure 1A). In addition, aCOP silencing
strongly inhibited EV71 replication in RD cells (Figure 1A). The
siRNA duplexes were almost as potent as positive control. And no
significant difference was observed between the two duplexes
(Figure 1A). The effect of f1COP silencing was also characterized.
When RD cells were pretreated with siRNA against f1COP,
transcript levels of f1COP and replication of EV71 were both
strongly inhibited compared to the control group (Figure 1B). This
was consistent with previous result, suggested that COPI was
required for EV71 replication. Depletion of COPI inhibited EV71
replication in cells.
However, when the activity of COPII was interrupted by
siRNA against Sec13p or Sec23p, EV71 replication remained as
efficient as control group (Figure 1C, 1D). As shown in Figure 1C,
in RD cells pretreated with Sec13p siRNA, the transcript levels of
Sec13p were strongly inhibited, but EV71 replication was not
notably altered compared with the negative control and mock
control. This was similar to the results when Sec23p was knocked
down by siRNA, in Figure 1D, EV71 replication was still strong.
This result indicated that COPII was dispensable to EV71
replication. Overall COPI, but not COPII, was required for viral
RNA synthesis in the infectious cycle.
COPI is required for EV71 production
To further test the dependence of viral protein synthesis and
virus production on COPI for EV71, aCOP and f1COP siRNAs
and nontargeting siRNA pretreated RD cells and mock treated
RD cells, were infected with EV71 at 0.1 MOI. Cells were
cultured at 37uC for an additional 24 hours. The yield of
infectious EV71 from equal numbers of cells was determined.
Viral protein VP1 and expression of aCOP and f1COP was
detected by western blotting. As shown in Figure 2A, while
nontargeting siRNA didn’t deplete aCOP expression, aCOP was
reduced to around one third by silencing siRNA duplexes
compared with mock control. Western blotting assay combined
with quantification analysis showed that as expression of aCOP
decreased, expression of viral protein VP1 also remarkably
reduced to around 30% compared with mock control and
negative control (Figure 2A). When COPI activity was interrupted
by f1COP depletion by siRNA, viral VP1 was also reduced
(Figure 2B). Viral titre in the supernatants was also detected. As
shown in Figure 2C, production of EV71 virions in the infectious
cycle was suppressed when aCOP or f1COP was knocked down.
A decrease of 3 to 4 orders of magnitude was observed. COPI is
required for EV71 viral protein synthesis and virions production.
COPI depletion protects RD cells from EV71 infection
To further test the effect of COPI on EV71 infection, RD cells
pretreated with silencing siRNA were infected with EV71 at 0.1
MOI. Nontargeting siRNA treated and mock treated cells were
infected as control. Viral infection and viral protein production
was determined by immunofluorescence staining of VP1 at 24 hpi.
In control group, around 40% cells were detected as red
fluorescence, indicating that these cells had been infected by
EV71 (Figure 3). The percentage of EV71 infected cells in
nontargeting siRNA treated cells was more or less. However, in
aCOP or f1COP depletion group, the red fluorescence was
notably reduced to 3–4%, suggested that EV71 infection was
inhibited (Figure 3). Silencing siRNA against COPI protected RD
cells from EV71 infection.
EV71 infection is inhibited by BFA
To further confirm that COPI activity is required for EV71
replication, we employed the pharmacologic COPI inhibitor BFA,
which blocks COPI coat assembly by inhibiting ARF-specific
guanine nucleotide exchange factors. As shown in Figure 4A, BFA
inhibited EV71 replication in a dose-dependent fashion, without
noticeable cytotoxicity. Trace quantities of BFA, lower than
10 ng/ml, allowed marked EV71 replication. However, EV71
RNA accumulation in infected cells was reduced as the
concentration of BFA increased, 20 ng/ml BFA inhibited EV71
replication effectively (Figure 4A). Replication of EV71 fell
substantially to 11% compared to the negative control, when
100 ng/ml BFA was used (Figure 4A).
Accumulation of viral VP1 protein was determined by in-cell
western blot. Cellular protein tubulin was used as internal control.
Consistent with previous result, when BFA concentration was
lower than 20 ng/ml, VP1 expression was not affected compared
to control group (Figure 4B). As the concentration increased, VP1
accumulation was noticeably reduced. In addition, 50–100 ng/ml
BFA markedly suppressed VP1 expression (Figure 4B). Also,
expression of cellular tubulin protein was unchanged as the BFA
concentration increased (Figure 4B). BFA inhibited EV71 protein
accumulation in a dose-dependent fashion.
Production of infectious EV71 virions was also assayed. As
expected, EV71 virion production was inhibited by BFA in a dose-
dependent manner (Figure 4C). Also, a remarkable reduction was
firstly observed when BFA concentration reached 20 ng/ml and
a decrease of 4 orders of magnitude was observed when 100 ng/
ml BFA was added (Figure 4C). Taken together EV71 infection
was inhibited by BFA in cells.
COPI, EV71 Replication
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guanine nucleotide exchange factor inhibitor to inhibit COPI
activity. To test whether EV71 replication could be inhibited by
GCA, 50 ng/ml GCA was added into the culture medium at the
time of infection. DMSO and 50 ng/ml BFA was used as negative
and positive control. Viral genome copies were monitored by
quantitative real-time PCR 24 hpi. As shown in Figure 4D, GCA
inhibited EV71 replication to a similar extent as BFA.
COPI is required downstream of viral entry
To determine whether depletion of COPI by siRNA treatment
affect EV71 entry into RD cells, viral genome copies for virions
during entry through endocytosis were monitored. As shown in
Figure 5A, in nontargeting siRNA pretreated RD cells, viral
genome copy numbers were unaltered compared with mock
treated group. Meanwhile, viral genome copies remained as many
as control group in aCOP and f1COP siRNA pretreated RD cells,
although copy numbers for aCOP and f1COP fell to around 30%
(Figure 5A). This result indicated that depletion of COPI didn’t
reduce EV71 entry into RD cells. Furthermore, 100 ng/ml BFA
and GCA inhibited EV71 replication when added up to 6 hpi in
Figure 5B, also suggesting COPI activity was required for a step in
the EV71 lifecycle postentry. Overall COPI is required down-
stream of viral entry.
COPI interact with viral protein 2C
To investigate interaction between COPI subunits and EV71
viral proteins, co-immunoprecipitation was performed. S-flag-tag
labeled viral nonstructural proteins, 2B, 2C, 3A and 3C, were
over-expressed in 293T cells. Co-immunoprecipitation was
performed by the S tag on the N-terminus according to the
manufacture’s procedure. As shown in Figure 6A, all four
nonstructural viral proteins were expressed at high level in cells
indicated by the flag tag detection. However, f1COP could be
only captured when co-immunoprecipitated with EV71 2C
protein, suggesting interaction between COPI and viral 2C
protein, but not 2B, 3A and 3C. The interaction was further
confirmed by GST pull-down assay. As shown in Figure 6B,
f1COP was captured by GST-2C, but not GST alone, indicating
that f1COP bound viral 2C protein in vitro. The interaction
between f1COP and 2C was further confirmed by pulling down
f1COP and testing viral 2C. As shown in Figure 6C, flag-tagged
2C was captured by anti-f1COP. Next, interaction between
aCOP and viral 2C was tested. In Figure 6D and 6E, aCOP was
also captured by viral 2C and vice versa. Taken together, these
results suggested interaction between COPI and viral 2C protein.
Discussion
Genomic siRNA screens can identify roles for genes and
biological pathways in viral infection by their function. This
technology has been successfully applied to the identification of
novel host dependency factors for HIV, HCV and DCV
[26,34,35,36]. In this study, we designed duplexes of siRNA
against COPI and COPII proteins, then conducted siRNA a loss-
of-function assay. We demonstrated that EV71 viral RNA
replication is dependent on COPI, but not COPII. The finding
that the COPI inhibitor, BFA and GCA, strongly inhibited EV71
replication further confirmed the dependence. The COPI proteins
interacted with viral protein 2C by co-immunoprecipitation assay
and GST pull-down assay.
Picornaviruses induce the formation of a cytoplasmic vesicular
compartment in infected cells and that this compartment is the
essential site of viral RNA replication. Previous studies showed
that membrane derived from the ER via a COPII coatomer-
Figure 1. COPI but not COPII is essential for EV71 replication. COPI subunits (A) aCOP and (B) f1COP silencing with two individual siRNA
duplexes blocked replication of EV71 (P,0.05). COPII subunits (C) Sec13p and (D) Sec23p depletion by siRNA was dispensable to EV71 replication
(P.0.05). Values were obtained from triplicate wells and are mean 6 SD.
doi:10.1371/journal.pone.0038035.g001
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with picornavirus replication [24,27]. Consistent with previous
results, our result suggested that the replication of EV71 was
dependent on COPI. However, compared with poliovirus de-
pendence on COPII, COPII seemed to be dispensable to EV71.
This might because of the limitation of our siRNA screen assay, or
because of the preference of EV71 for COPI.
BFA is a fungal metabolite used to study membrane traffic in
eukaryotic cells. BFA blocks protein transport from the ER to the
Golgi apparatus [37,38]. BFA prevents membrane binding of
COPI and formation of COPI-coated vesicles [39,40], while the
formation of COPII-coated vesicles is not affected [41,42]. BFA
also prevents budding of clathrin-c-adaptin-coated vesicles from
the Golgi apparatus, endosomes, and lysosomes [43,44]. However,
replication of poliovirus was not affected in cells in which clathrin-
c-adaptin association with membranes was inhibited [45]. Similar
to BFA, GCA was also shown to inhibit ARF inactivation and to
block COPI activity. Both BFA and GCA strongly inhibited EV71
replication. Thus, our results, in combination with the published
data, strongly suggest the inhibitory effect of BFA is due to
prevention of COPI activity.
In addition to structural proteins, picornaviruses produce
several precursor polyproteins and mature protein products.
Because of the limited coding capacity of picornavirus genomes,
both the precursors and mature products actively participate in
viral processes and are involved in the assembly of replication
initiation complexes and mediate the process of RNA synthesis. In
this study, we conducted a co-immunoprecipitation assay with four
viral proteins: 2B, 2C and 3A, 3C. aCOP and f1COP was
captured by 2C, suggesting interaction between 2C and COPI.
GST pull-down assay confirmed the interaction. Together with
poliovirus, 2C induces intracellular membrane rearrangement and
Figure 2. COPI is required for EV71 production. (A) aCOP, (B) f1COP silencing with two individual siRNA duplexes blocked EV71 viral protein
VP1 expression by Western blotting with the indicated antibodies (P,0.05). Quantification analysis of EV71 VP1 synthesis was performed by Image J.
Standard deviations of three independent experiments are shown. (C) aCOP and f1COP depletion by siRNA inhibited EV71 virions production
(P,0.05). Values were obtained from triplicate wells and are mean 6 SD.
doi:10.1371/journal.pone.0038035.g002
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a poliovirus mutant carrying mutations on 2C protein was
resistant to BFA [48], this result indicated EV71 2C protein
could be involved in the recruitment of COPI into the replication
complex.
Picornaviruses usually disrupt the secretory pathway in infected
cells, which could include a block in the secretion of interferons
and proinflammatory cytokines or the inhibition of cell surface
MHC class 1 expression and antigen presentation. Poliovirus 3A,
2B, 2C and 2BC proteins are identified as involved in this process
[49,50,51]. The 3A protein of coxsackievirus B3 (CVB3) and
poliovirus was shown to interact with GBF1, a guanine nucleotide
exchange factor for ARF, and block COPI assembly [52,53].
Mutations in 3A rescue growth of poliovirus and CVB3 in the
presence of BFA [54,55]. For foot-and-mouth disease virus
(FMDV), viral proteins 2B, 2C and 2BC block endoplasmic
reticulum-to-Golgi transport [56,57]. Similar roles for EV71 have
not yet been identified. Our finding that EV71 2C protein could
interact with COPI is consistent with previous result that FMDV
2C protein could colocalize with f1COP to the Golgi apparatus,
and arrest transport within the Golgi apparatus [57], which might
suggest that EV71 2C functions the same way as FMDV 2C in
disruption of the secretory pathway in infected cells. However,
BFA has little effect on FMDV replication suggesting FMDV may
acquire cellular membranes into its replication complexes in
a manner different from that of EV71, while the block of secretion
by 2C has the potential to contribute to the development of
persistent infections rather than viral RNA replication [31].
Finally, the fact that inhibition of COPI could protect cells from
EV71 infection, suggests a novel approach to viral inhibition.
Since no effective therapy is available for the treatment of EV71
infection, modulating host COPI activity could be a promising
new direction for antiviral drug discovery.
Materials and Methods
Cell culture and drug treatment
Rhabdomyosarcoma (RD, ATCC, USA) cells and HEK293T
(293T, ATCC, USA) cells were propagated and maintained in
Minimum Essential Medium (MEM, HyClone, Logan, USA) and
Dulbecco’s Modified Eagle Medium (DMEM, HyClone, Logan,
USA) supplemented with 10% fetal bovine serum (FBS)
(Invitrogen, CA, USA) and 100 U/ml penicillin, and 100 mg/
ml streptomycin at 37uC with 5% CO2. Brefeldin A (BFA,
Sigma-Aldrich, St. Louis, USA) was dissolved in ethanol and
stored at 1 mg/ml in 4uC before use. Golgicide A (GCA, Sigma-
Aldrich, St. Louis, USA) was dissolved in dimethyl sulfoxide
(DMSO) and stored at 1 mg/ml. BFA and GCA were added to
cell cultures in a concentration series at the time of infection or
indicated time.
Virus infection
EV71 strain (Shzh-98, GenBank accession no. AF302996) was
used. Viruses were propagated in RD cells and infected at 0.1
multiplicity of infection (MOI) per cell, measured as 50% tissue
culture infectious doses (TCID50).
Plasmid construction
For transient expression in 293T cell, EV71 2B, 2C and 3A, 3C
were cloned from EV71 Shzh-98 strain and constructed into
pcDNA3 vector (Invitrogen, CA, USA) under the control of CMV
promoter. A S-protein tag (KETAAAKFERQHMDS) and a Flag
tag (DYKDDDDK) were tandem anchored on the N- terminus of
these proteins for co-immunoprecipitation and western blotting.
For expression and purification of GST-fused 2C protein, EV71
2C was constructed in the pGEX-6P-1 vector (GE Healthcare, NJ,
England) to generate pGEX-6P-2C. The nucleotide sequences of
the plasmids and the orientation of the inserted fragments were
verified by sequencing.
siRNA design and transfection
The siRNAs were designed using a Web-based siRNA tool
BLOCK-iTTM RNAi Designer (Invitrogen, https://rnaidesigner.
invitrogen.com/rnaiexpress/) and were custom synthesized by
Invitrogen (CA, USA). Sequences are in Table 1. siRNA targeting
the EV71 VP2 protein was synthesized according to the Stealth-
990 sequence and used as a positive control [33]. Stealth RNAi
siRNA Negative Control Med GC (Invitrogen, CA, USA) was
Figure 3. COPI depletion protects RD cells from EV71 infection. RD cells were transfected with aCOP and f1COP siRNA and infected with
EV71. At 24 hpi, cells were fixed with 4% paraformaldehyde and permeabilized. EV71 infection was determined by immunofluorescence staining on
VP1. RD cells were observed by DAPI.
doi:10.1371/journal.pone.0038035.g003
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transfection using Oligofectamine Reagent (Invitrogen, CA, USA)
according to the manufacturer’s instructions. RD cells were
cultured overnight until 40% confluence before use; 100 pmol
siRNA was incubated in 60 ml Opti-MEMH (Invitrogen, CA,
USA) for 15 min at room temperature (RT), while 5 ml
Oligofectamine was incubated with 15 ml Opti-MEM. The siRNA
and Oligofectamine were mixed and incubated for 20 min at RT
before addition to cell cultures. The culture medium was changed
4 hr later and cells were cultured 72 hr before virus infection.
Quantitative real-time PCR
Total cellular RNA and viral RNA were extracted from each
well using RNAeasy Mini kit (Qiagen, Hilden, Germany) at 24 hpi
according to the manufacturer’s instructions. Reverse transcribed
PCR was conducted using Superscript First-Strand Synthesis
System (Invitrogen, CA, USA) in 20 ml with 1.2 mg total RNA
according to the manufacturer’s protocol. Relative quantitative
real-time PCR was conducted on an ABI Prism 7000 Real-time
PCR System (Applied Biosystems, CA, USA) by using a Power
SYBR Green PCR Master Kit (Applied Biosystems, CA, USA).
Reactions were 2 ml cDNA, 1 ml of each primer and 25 ml Power
SYBR Green PCR Master Mix in 50 ml. Efficiency-corrected
relative quantitation was used with GAPDH as an internal control
[58]. Primer sequences are in Table 2.
Western blotting
RD cells were collected 24 hpi and washed with PBS twice and
lysed in buffer containing 100 mM NaCl, 20 mM Tris (pH 8.0),
0.5% NP-40, 0.25% sodium deoxycholate, 1 mM EDTA with
proteinase inhibitor cocktail. Supernatant was collected after
centrifuged at 13,000 rpm/min for 15 min and separated by
electrophoresis in denaturing 4 to 10% SDS-PAGE and trans-
ferred to nylon polyvinylidene difluoride (PVDF) membranes
Figure 4. EV71 infection is inhibited by BFA. RD cells were infected with EV71 at 0.1 MOI with various concentrations of BFA. (A) Concentrations
of 20 ng/ml BFA or higher significantly inhibited EV71 replication (P,0.05). Standard deviations of three independent experiments are shown. (B)
Viral VP1 protein and internal cell tubulin protein was detected by in-cell Western blot. Concentrations of 20 ng/ml or higher BFA inhibited VP1
expression. (C) Viral titre was suppressed by 20 ng/ml or higher BFA (P,0.05). Standard deviations of three independent experiments are shown. (D)
50 ng/ml GCA inhibited EV71 replication in RD cells (P,0.05). Standard deviations of three independent experiments are shown.
doi:10.1371/journal.pone.0038035.g004
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nonfat dry milk and probed with primary antibodies as indicated
at 4uC overnight, followed by incubation with the corresponding
IRD Fluor 680-labeled IgG or IRD Fluor 800-labeled IgG
secondary antibody (Li-Cor Inc., NE, USA). After washing,
membranes were scanned using an Odyssey Infrared Imaging
System (Li-Cor, NE, USA) at the recommended wavelength and
analyzed with Odyssey software. Molecular sizes of proteins were
determined by comparison with prestained protein markers
(Fermentas, Maryland, USA). EV71 capsid protein VP1 was
detected by anti-EV71 VP1 monoclonal antibody (eENZYME,
Maryland, USA). aCOP and f1COP were detected by rabbit anti-
aCOP and anti-f1COP antibody (ABcam, Cambridge, England).
GST or GST-fused 2C protein were identified with mouse anti-
GST (Beyotime, Suzhou, China) and corresponding secondary
antibody. To control for protein loading, levels of housekeeping
protein GAPDH were assessed using mouse anti-GAPDH
(Beyotime, Suzhou, China) and IRD Fluor 680-labeled IgG
secondary antibody (Li-Cor Inc., NE, USA). Quantification
Figure 5. COPI is required downstream of viral entry. (A) Cells were pretreated with siRNA, infected at 4uC to allow surface binding, followed
by 3 hr at 25uC to resume endocytosis. Viral entry was measured by determining viral genome copies, which was almost unchanged between COPI
knocked down group and control group (P.0.05). (B) BFA and GCA inhibited EV71 replication (P,0.05), when added up to 6 hpi. RD cells were
infected with at 0.1 MOI and harvested at 24 hpi. The experiment was performed in triplicate, and the bars represent means 6 SD.
doi:10.1371/journal.pone.0038035.g005
Figure 6. COPI interact with viral protein 2C. (A) At 24 hpt, immunoprecipitation was conducted with S beads and western blotting was carried
out as indicated. (B) GST pull-down was performed with 293T cell lysates. Western blotting detection was carried with indicated antibodies. (C)
Immunoprecipitation was conducted with Protein A agarose plus anti-f1COP antibody and western blotting was carried out as indicated. (D)
Immunoprecipitation was conducted with S beads and western blotting was carried out as indicated. (E) Immunoprecipitation was conducted with
Protein A agarose plus anti-aCOP antibody and western blotting was carried out as indicated.
doi:10.1371/journal.pone.0038035.g006
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Image J.
Immunofluorescence staining
RD cells were pretreated with silencing siRNA or negative
control siRNA for 72 hr and infected with EV71 at 0.1 MOI. At
24 hpi, cells were fixed with 4% paraformaldehyde for 30 min and
permeabilized with 0.5% Triton X-100 for 30 min at RT.
Samples were washed twice with PBS and blocked with 5% goat
serum and incubated with mouse anti-EV71 VP1 (eENZYME,
Maryland, USA) for 60 min. After washed twice with PBS,
samples were incubated with Alexa Fluor 568 rabbit anti-mouse
IgG (Invitrogen, CA, USA) for another 30 min. Cells were
counterstained with DAPI to visualize nuclear DNA.
In-cell Western blot analysis
In-cell Western blot analyses were performed as described
previously [59]. siRNA pre-treated RD cells were cultured at 37uC
with 5% CO2 for 72 hr and infected with EV71 at 0.1 MOI. At
24 hpi, cells were fixed with 4% paraformaldehyde for 30 min and
permeabilized with 0.5% Triton X-100 for 15 min at RT. Cells
were washed twice with PBS and incubated with anti-EV71 VP1
monoclonal antibody (eENZYME, Maryland, USA) and mouse
anti-tubulin (Beyotime, Suzhou, China) overnight at 4uC. The
next day, cells were washed with 0.1% Tween-20 in PBS and
incubated with goat anti-mouse 680 (1:500) (Li-Cor, NE, USA).
After washing twice with PBST and twice with PBS, cells were
scanned using an Odyssey Infrared Imager (Li-Cor Inc., NE,
USA).
Viral titre assay
Virus titre in supernatants was determined as TCID50 on RD
cells by the Reed-Muench method [60]. Results were obtained in
three independent experiments and the representative results are
shown.
Viral entry assay
Cells were pretreated with siRNA for 3 days and placed at 4uC
to block endocytosis. Virions were added at 5 MOI and incubated
for 2 h to be allowed to bind to the surface of RD cells. The cells
were washed twice with PBS to remove unbound virions and then
incubated at room temperature to resume endocytosis. Three
hours later, total cellular RNA and viral RNA was extracted and
determined by quantitative real-time PCR to monitor virions
during entry.
Transfection and Co-immunoprecipitation assay
Cell transfection was performed using Lipofectamine 2000
(Invitrogen, CA, USA) following the manufacturer’s protocol.
Briefly, 10 mg of plasmids were mixed with 30 ml Lipofectamine
2000 and incubated at RT for 20 min before added into cell
culture. Transfected 293T cells were cultured for another 24 hr.
Cells were collected and lysed in buffer containing 100 mM
NaCl, 20 mM Tris (pH 8.0), 0.5% NP-40, 0.25% sodium
deoxycholate, 1 mM EDTA with proteinase inhibitor cocktail.
The supernatants were cleared at 14,000 rpm to remove debris
and incubated with S protein beads (Novagen, Darmstadt,
Germany) overnight at 4uC. The immunocomplexes were
recovered by a brief centrifugation and washed three times with
PBS and subjected to SDS-PAGE. Protein bands were detected
by western blotting. Reciprocal co-immunoprecipitation assay
was conducted by Protein A agarose (Invitrogen, CA, USA) plus
2 mg Goat anti-aCOP/anti-f1COP antibody (ABcam, Cam-
bridge, England) with cell protein extract overnight at 4uC. The
immunocomplexes were recovered by a brief centrifugation and
washed three times then subjected to SDS-PAGE for western
blotting detection with anti-flag antibody.
GST pull-down assay
To further confirm the interaction between COPI complex and
EV71 2C protein, a GST pull-down assay was assessed. Total
protein was extracted from about 5610
7 293T cells in buffer
containing 100 mM NaCl, 20 mM Tris (pH 8.0), 0.5% NP-40,
0.25% sodium deoxycholate, 1 mM EDTA with proteinase
inhibitor cocktail. Cell debris was removed by centrifugation.
Recombinant GST-2C and GST alone were expressed in
Escherchia coli BL21 strain and purified using glutathione beads
according to standard protocols. GST–2C and GST alone was
incubated with 293T cell protein extract at 4uC for 2 hr.
Glutathione beads were recovered by a brief centrifugation and
washed three times with PBS before resolved by SDS-PAGE and
detected by western blotting.
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Table 1. siRNA sequences used in this study.
Target Gene Duplex Sense Sequence
aCOP 1 59-GGCGCAUGAAUGAAUCAAATT-39
25 9-GGCCAUUACAACAAUGUAUTT-39
f1COP 1 59-CCAAAGAACAGAUCAAGUGTT-39
25 9-GGCUGUGGAUGAAAUUGUATT-39
Sec13p 1 59- CUUUGAUGUGCGCAAUGGATT-39
25 9-GAAGAUCAACAACGCUCACTT-39
Sec23p 1 59-UAUGAACCUGUGCUUUGCATT-39
25 9GAUCUCCAUUUCUUCAAGUTT-39
Stealth-990 59-GCGCAAUUAACUAUUGGCAACUCCA-39
*Stealth-990 corresponds to the siRNA against EV71 VP2.
doi:10.1371/journal.pone.0038035.t001
Table 2. Quantitative real-time PCR primers.
Target Forward Primer Reverse Primer
EV71 CCCCTGAATGCGGCTAAT CAATTGTCACCATAAGCAGCCA
aCOP CCTGGGATGAGAGTGGGGTAT AGTGCTTTGGCTGCTTCC
f1COP AAGATGGAGGCGCTGATTTT ACACTGGGGTAGGTGTCGTC
Sec13p ACGAGCATGCGGGACACGACT TGGGAGCAGCTGGCGATGGT
Sec23p TGTGCCCTTGATCAAACTGGA
CTT
GATAATGCGTGACAAACTGGAT
GG
GAPDH CTCTGCTCCTCCTGTTCGAC TTAAAAGCAGCCCTGGTGAC
doi:10.1371/journal.pone.0038035.t002
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